Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Gabapentin for PSH in TBI
NCT05427474Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of propranolol and gabapentin in Paroxysmal Sympathetic Hyperactivity (PSH) (3 arms), sponsored by Zagazig University. Primary endpoint: Mortality Rate at 8 months. Status: unknown.
02
Drugs
propranololgabapentin
03
Conditions
Paroxysmal Sympathetic Hyperactivity (PSH)
Beyond the preview
Go deeper on NCT05427474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427474.